BCAX

In the past six months, Bicara Therapeutics (BCAX) reported a Q2 2026 EPS loss of -$0.82, matching estimates, which, along with increased operating expenses, caused a temporary stock dip. The company announced inducement grants on October 5, September 3, and August 14, 2026. Analyst coverage has been positive, with BMO initiating coverage at Outperform, Goldman Sachs raising its price target to $20, Wedbush raising its target to $33, and Citigroup and Cantor Fitzgerald reiterating 'market outperform' and 'overweight' ratings. The stock has been volatile, with a 52-week range of $13.70 to $30.99. On October 13, 2025, shares rose after the FDA granted Breakthrough Therapy Designation to ficerafusp alfa in combination with pembrolizumab for certain HNSCC patients.